Vaxcyte, Inc. consummated a combined capital raise of approximately $1.08 billion on October 9, 2026. The company issued $575 million in aggregate principal amount of 1.50% Convertible Senior Notes due 2032, which carry an initial conversion price of approximately $89.60 per share and mature on October 15, 2032. Concurrently, Vaxcyte sold 8,584,375 shares of common stock and pre-funded warrants at a public price of $64.00 per share, generating net proceeds of approximately $544.3 million after underwriting discounts. The debt offering generated net proceeds of approximately $558.7 million. Vaxcyte is a biotechnology company focused on developing vaccines for infectious diseases.
